Abstract

The objective of this study was to identify clinical predictive factors for tumor response after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC). All factors were evaluated in 88 patients with LARC treated with nCRT. After a long period of 4-8 weeks of chemoradiotherapy, 3 patients achieved clinical complete response (cCR) and thus aggressive surgery was avoided, and the remaining 85 patients underwent a curative-intent operation. The response to nCRT was evaluated by tumor regression grade (TRG) system. There were 32 patients (36.4%) with good tumor regression (TRG 3-4) and 56 (63.6%) with poor tumor regression (TRG 0-2). Lymphocyte counts and ratios were higher in good response cases (P=0.01, 0.03, respectively) while neutrophil ratios and N/L ratios were higher in poor response cases (P=0.04, 0.02, respectively). High lymphocyte ratios before nCRT and good tumor regression (TRG3-4) were significantly associated with improved 5-year disease-free survival (P<0.05). Pretreatment nodal status was also significantly associated with 5-year disease-free survival and 5-year overall survival (P<0.05). Multivariate analysis confirmed that the pretreatment lymphocyte ratio and lymph nodal status were independent prognostic factors. Our study suggested that LARC patients with high lymphocyte ratios before nCRT would have good tumor response and high 5-year DFS and OS.

Highlights

  • Neoadjuvant chemoradiotherapy followed by radical resection has been the standard treatment for patients with locally advanced rectal cancer (LARC), showing to reduce postoperative locoregional recurrence and improve postoperative survival

  • Our study suggested that LARC patients with high lymphocyte ratios before neoadjuvant chemoradiotherapy (nCRT) would have good tumor response and high 5-year disease-free survival (DFS) and overall survival (OS)

  • Lymph node status is significantly different in two groups (P=0.02) and none of other factors were significantly associated with the tumor regression grade

Read more

Summary

Introduction

Neoadjuvant chemoradiotherapy followed by radical resection has been the standard treatment for patients with LARC, showing to reduce postoperative locoregional recurrence and improve postoperative survival. High lymphocyte ratios before nCRT and good tumor regression (TRG3-4) were significantly associated with improved 5-year disease-free survival (P

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call